Tag: cardiovascular disease

New option for chronic kidney failure patients emerges as Ozempic trial...

Ozempic (Novo Nordisk) is a once-daily injection with US Food and Drug Administration (FDA) approval for use as a preventative treatment for strokes and...

Empagliflozin recommended for CKD by European Medicines Agency body

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance (empagliflozin) for...

Young kidney cancer survivors face “significantly elevated” heart risks

Cardiovascular disease is a leading cause of health complications and death among adolescents and young adults (AYAs) diagnosed with cancer, where AYAs are characterised...

Invizius announces ‘angry blood’ haemodialysis study and recruits 300th patient

Invizius, a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, has announced that it has recruited its...

Proteomic tool promises prediction of cardiovascular risk in CKD patients

A new proteomic risk model for cardiovascular disease in chronic kidney disease (CKD) patients has been found to be more accurate than current methods...

Late-breaking clinical trials reinforce importance of early detection and treatment in...

Three late-breaking clinical trials presented at the 59th European Renal Association (ERA) congress (19–22 May, Paris, France) have placed increased focus on the need...

Pilot study of third COVID-19 vaccine dose in kidney transplant recipients...

A pilot study has begun to assess the antibody response to a third dose of an authorised COVID-19 mRNA vaccine in kidney transplant recipients...